Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1617 1643 1645 1646
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18210885 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | Non-Final OA | Janssen Biotech, Inc. |
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | Final Rejection | GENENTECH, INC. |
| 17381145 | IMMUNOGLOBULIN A ANTIBODIES AND METHODS OF PRODUCTION AND USE | Non-Final OA | GENENTECH, INC. |
| 18484361 | Methods for Producing Fabs and IgG Bispecific Antibodies | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17910327 | AFFINITY MATURED AND HUMANIZED BINDING DOMAINS TARGETING ROR2 | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED |
| 17257391 | ANTIBODY TUMOR-TARGETING ASSEMBLY COMPLEXES | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17481578 | SERUM ALBUMIN-BINDING IMMUNOGLOBULIN VARIABLE DOMAINS | Non-Final OA | Sanofi |
| 17907781 | SELECTIVE MODULATION OF TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY SIGNALING VIA MULTI-SPECIFIC ANTIBODIES | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18414892 | BCMA Monoclonal Antibody-Drug Conjugate | Non-Final OA | MedImmune, LLC |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | Non-Final OA | MACROGENICS, INC. |
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | Final Rejection | MacroGenics, Inc. |
| 18453107 | COMBINED THERAPEUTIC USE OF ANTIBODIES AND IMMUNOGLOBULIN G-DEGRADING ENZYMES | Final Rejection | Hansa Biopharma Limited |
| 17786708 | POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME | Non-Final OA | KISOJI BIOTECHNOLOGY INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy